

Antiretroviral and Directly Acting Antiviral Drug Metabolism and Transporter Characteristics (Summary)

	Substrate	CYP450 and UGT		Transporters	
		Inhibitor	Inducer	Inhibitor	Inducer
ANTIRETROVIRALS					
HIV PROTEASE INHIBITORS (PIs)					
atazanavir ¹	Mainly CYP3A P-gp, MRP1	3A4, UGT1A1 >>2C8 (weak)* *Caution when unboosted atazanavir is coadministered with 2C8 substrates with narrow therapeutic indices (e.g., paclitaxel, repaglinide); clinically significant interactions with 2C8 substrates are not expected when atazanavir is boosted with ritonavir.		P-gp, MRP1, OATP1B1, OATP1B3, BCRP	
darunavir ²	Mainly CYP3A, P-gp	CYP3A4		BCRP, OATP1B1 ³	
fosamprenavir ⁴ , indinavir ⁵ , lopinavir/ritonavir ⁶ , saquinavir ⁷	Mainly CYP3A, P-gp, MRP1 (LPV, SQV)	CYP3A4 (saquinavir is a weak inhibitor)		P-gp (LPV) OATP1B1, OATP1B3 (LPV, SQV)	
nelfinavir ⁸	Mainly CYP3A, 2C19, P-gp	CYP3A4	UGT, 2B6, 2C8, 2C9/19 ⁹		
tipranavir ¹⁰	Mainly CYP3A, P-gp	2D6 ¹¹	CYP3A4 (potent) ¹⁰ , UGT	OATP1B1	P-gp
PK BOOSTERS					
ritonavir ¹²	CYP3A4, P-gp, MRP1	CYP3A4 (potent) > >2D6* >2C9 >2C19 >2A6 >1A2 >2E1. *negligible effect at boosting doses ⁶	UGT, CYP1A2, CYP2C9/19, 2B6 (inhibits in vitro, ¹³ but induces in vivo ¹⁴)	P-gp, OATP1B1, OATP1B3, BCRP, OATP2B1, OCT2, MATE1 ¹⁵	
cobicistat ¹⁶	CYP3A, 2D6 (minor)	CYP3A, CYP2D6		P-gp, BCRP, OATP1B1 and OATP1B3, MATE1 ^{15, 17}	
HIV NNRTIs					
dapivirine <i>*administered via vaginal ring with low systemic concentrations, reducing likelihood of clinically relevant DDIs¹⁸</i>	CYP3A4/5 > 2B6, 2C19; UGT isoenzymes ¹⁹		Does not induce CYP1A2 or CYP3A4/5 activity (in cultured human hepatocytes). ¹⁹		
delavirdine ²⁰	CYP3A4	3A4 (potent)			
doravirine ²¹	CYP3A4/5. Not a	Does not inhibit CYP3A4,	Unlikely to induce	Not likely to inhibit P-	

Antiretroviral and Directly Acting Antiviral Drug Metabolism and Transporter Characteristics (Summary)

	Substrate	CYP450 and UGT		Transporters	
		Inhibitor	Inducer	Inhibitor	Inducer
	substrate of OATP1B1	2D6, 1A2, 2B6, 2C8/9, 2C19, or UGT1A1.	CYP1A2, 2B6 or 3A4 enzymes to a clinically relevant extent.	glycoprotein, OATP1B1/3, OAT1, OAT3, OCT2, MATE1, MATE2K, BCRP, BSEP.	
efavirenz ²²	CYP3A4, 2B6 (minor)	2C9, 2C19 ²² (? Clinical significance).	3A4 (potent), 2B6 ²³ , UGT1A1 ²⁴		OATP1B1, MRP2 ²⁵
etravirine ²⁶	CYP3A4, CYP2C9, and CYP2C19	CYP2C9 (weak), CYP2C19 (moderate), p-glycoprotein (weak)	3A4 (weak)	P-gp (weak; 19% increase Cmax of digoxin) ²⁷	
nevirapine ²⁸	CYP3A4, 2B6 (minor)		3A4, 2B6 (potent)		
rilpivirine ²⁹	CYP3A4 (major); CYP2C19, 1A2, 2C8/9/10 (minor).		2C19 (moderate), CYP1A2, 2B6 and 3A4 (weak). ³⁰ A clinically relevant effect on CYP enzyme activity is considered unlikely with the 25 mg dose.	OCT2	
HIV INSTIs					
bictegravir ^{31, 32}	UGT1A1, CYP3A4 (similar contribution)	Does not inhibit CYP including CYP3A4 or UGT1A1.	Does not induce CYP3A4 or UGT1A1.	OCT2 (less than dolutegravir), MATE1. Does not inhibit OATP1B1/3, OCT1, BSEP, OAT1/3.	
cabotegravir ^{33, 34}	UGT1A1, UGT1A9 (minor). Substrate of P-gp, BCRP (high intrinsic membrane permeability limits impact of these transporters on intestinal absorption).	Does not inhibit CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19 or 2D6. Weakly inhibits CYP3A4 (10% ↑ midazolam AUC) and inhibits UGT1A3 (not clinically relevant).	Does not induce CYP1A2, 2B6 or 3A4.	OAT1/3 (weak; not anticipated to cause clinically significant drug interactions). ³⁵ Does not inhibit P-gp, BCRP, BSEP, MRP2, MRP4, OCT1, OCT2, MATE1, OATP1B1, OATP1B3.	
dolutegravir ³⁶	UGT1A1, CYP3A4 (10-15%); also a substrate of UGT1A3, UGT1A9, P-gp and BCRP in vitro. Not a substrate of OATP1B1, OATP1B3,		Does not induce CYP1A2, CYP2B6, or CYP3A4 in vitro.	OCT2, MATE1; also MATE2 but low potential to affect transport of MATE2 substrates.	

Antiretroviral and Directly Acting Antiviral Drug Metabolism and Transporter Characteristics (Summary)

	Substrate	CYP450 and UGT		Transporters	
		Inhibitor	Inducer	Inhibitor	Inducer
	or OCT1.				
elvitegravir ³⁷	CYP3A4		CYP2C9 (modest)		
raltegravir ³⁸	UGT1A1	Raltegravir has no inhibitory or inductive potential in vitro.	Raltegravir has no inhibitory or inductive potential in vitro.		
HIV REVERSE TRANSCRIPTASE NUCLEOTIDE INHIBITORS (NRTIs)					
abacavir	Metabolized by intracellular kinases to carbovir triphosphate (CBV-TP). Metabolized by alcohol dehydrogenase and glucuronidation pathways.	CYP1A1 ³⁹			
tenofovir alafenamide (TAF) ⁴⁰	P-gp, BCRP; minimal metabolism via 3A4	3A4 (weak – in vitro only; not an inhibitor in vivo). Does not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or UGT1A.	Not an inducer of 3A4 in vivo.		
tenofovir disoproxil fumarate (TDF) ⁴¹	OAT1, MRP4 ⁴²	Does not inhibit CYP3A4, 2D6, 2C9, 2E1. Inhibits CYP1A but likely not clinically significant.			
HIV NUCLEOSIDE REVERSE TRANSCRIPTASE TRANSLOCATION INHIBITOR (NRTTI)					
islatravir ⁴³	Does not interact with CYP enzymes.	Does not inhibit CYP enzymes in vitro.	Does not induce CYP enzymes in vitro.	Does not interact with renal or hepatic transporters, incl. P-gp, OATP1B1/3, MRP2/3/4, BSEP, OCT1, OCT2, OAT3, BCRP, MATE1/2K.	
HIV ATTACHMENT INHIBITOR					
fostemsavir (Rukobia) (prodrug of temsavir) ⁴⁴	Esterases (36.1%), CYP3A4 (21.2%), P-gp, BCRP *FOS is contraindicated with	Not anticipated to inhibit UGT1A1, 1A4, 1A9 or CYP450 enzymes.	No CYP3A4 induction.	Inhibitor of OATP1B1, OATP1B3 and BCRP. Not anticipated to inhibit other transporters including	

Antiretroviral and Directly Acting Antiviral Drug Metabolism and Transporter Characteristics (Summary)

	Substrate	CYP450 and UGT		Transporters	
		Inhibitor	Inducer	Inhibitor	Inducer
	strong CYP3A4 inducers. Coadministration with moderate CYP3A4 inducers and/or strong CYP3A4, P-gp and/or BCRP inhibitors are not anticipated to have a clinically relevant effect on temsavir plasma concentrations ⁴⁴			OCT2, OAT1, OAT3, MATE1, MRP2, BSEP, Ntcp and P-gp.	
HIV CAPSID INHIBITOR					
lenacapavir (Sunlenca) ⁴⁵ *long acting SC injection with oral lead in	Substrate of UGT1A1, CYP3A4 (minor), P-gp. May use with potent CYP3A4/Pgp inhibitors without dose modification. Avoid with potent CYP/P-gp/UGT inducers. <i>Low hepatic clearance (0.8%) in primary human hepatocytes⁴⁶</i>	CYP3A4 (moderate) 94% increase Cmax, 233% increase AUC of midazolam.		P-gp, BCRP (weak) 24% increase Cmax, 63% increase AUC of TAF; 58% increase Cmax, 30% increase AUC of rosuvastatin. No effect on OATP. No change in pitavastatin Cmax or AUC.	
HIV CCR5 INHIBITORS					
cenicriviroc ⁴⁷	CYP3A4, 2C8. Not a substrate of OATP1B1/B3 or OCT2.	Not a known CYP inhibitor.	Not a known CYP inducer.	P-gp Not an inhibitor of OATP1B1/B3 or OCT2.	
maraviroc ⁴⁸	CYP3A4, P-gp	Does not inhibit major CYP isozymes at clinically relevant concentrations.		P-gp (in gut; systemic effects unlikely).	
HIV NUCLEOSIDE REVERSE TRANSCRIPTASE TRANSLOCATION INHIBITOR (NRTTI)					
islatravir ⁴³	Does not interact with CYP enzymes.	Does not inhibit CYP enzymes in vitro.	Does not induce CYP enzymes in vitro.	Does not interact with renal or hepatic transporters, incl. P-gp, OATP1B1/3, MRP2/3/4, BSEP, OCT1, OCT2, OAT3,	

Antiretroviral and Directly Acting Antiviral Drug Metabolism and Transporter Characteristics (Summary)

	Substrate	CYP450 and UGT		Transporters	
		Inhibitor	Inducer	Inhibitor	Inducer
				BCRP, MATE1/2K.	
HIV MATURATION INHIBITOR (MI)					
GSK2838232 ⁴⁹	CYP3A4, UGT	UGT1A4. Inhibits intestinal CYP3A4 (when administered as GSK232 200 mg/ritonavir).	CYP3A4 (weak)	Inhibits intestinal P-gp, BCRP (when administered as GSK232 200 mg/ritonavir).	
CO-FORMULATED/COMBINATION HEPATITIS C REGIMENS					
Epclusa®					
velpatasvir ⁵⁰⁻⁵² (NS5A inhibitor)	CYP3A4, 2C8, 2B6; OATP1B1, OATP1B3, P-gp, BCRP.	No inhibiting or inducing effects on P450.	No inhibiting or inducing effects on P450.	P-gp, OATP1B1, OATP1B3, BCRP (limited to intestinal efflux and hepatic uptake – clinically relevant interactions in systemic circulation not expected).	
sofosbuvir ⁵³ (NS5B inhibitor)	P-gp, BCRP.GS-331007 (primary systemic nucleoside metabolite, accounts for >90% of systemic drug exposure): not a P-gp substrate	No inhibiting or inducing effects on P450 and UGT1A1.	No inhibiting or inducing effects on P450 and UGT1A1.	No inhibiting or inducing effects on P-gp, BCRP, OATP1B1, OATP1B3, OCT1, BSEP.	No inhibiting or inducing effects on P-gp, BCRP, OATP1B1, OATP1B3, OCT1, BSEP.
Harvoni®					
ledipasvir ⁵⁴ (NS5A inhibitor)	P-gp, BCRP	Not an inhibitor or inducer of P450 or UGT.	Not an inhibitor or inducer of P450 or UGT.	Weak inhibitor of P-gp and BCRP (intestinal, not systemic). Inhibitor of OATP1B1/1B3 only at concentrations exceeding those achieved in clinic.	
sofosbuvir ⁵³ (NS5B inhibitor)	P-gp, BCRP.GS-331007 (primary systemic nucleoside metabolite, accounts for	No inhibiting or inducing effects on P450 and UGT1A1.	No inhibiting or inducing effects on P450 and UGT1A1.	No inhibiting or inducing effects on P-gp, BCRP, OATP1B1, OATP1B3, OCT1,	No inhibiting or inducing effects on P-gp, BCRP, OATP1B1,

Antiretroviral and Directly Acting Antiviral Drug Metabolism and Transporter Characteristics (Summary)

	Substrate	CYP450 and UGT		Transporters	
		Inhibitor	Inducer	Inhibitor	Inducer
	>90% of systemic drug exposure): not a P-gp substrate.			BSEP.	OATP1B3, OCT1, BSEP.
Maviret® (Mavyret® – US)⁵⁵					
glecaprevir (ABT-493) (NS3/4A PI)	P-gp and/or BCRP.	CYP1A2, 3A4 (27% ↑ midazolam AUC) and UGT1A1 (weak); do not inhibit CYP2D6, 2C19, 2C9. Significant interactions with substrates of these enzymes are not expected. ⁵⁶		P-gp (105% ↑ Cmax, 138% ↑ AUC dabigatran), BCRP, OATP1B1/3.	
pibrentasvir (ABT-530) (NS5A inhibitor)	Also for glecaprevir: OATP1B1/3, CYP3A4 (secondary role). Minimal metabolism and primary biliary excretion, negligible renal excretion (<1%).				
Vosevi®					
sofosbuvir ⁵³ (NS5B inhibitor)	P-gp, BCRP. GS-331007 (primary systemic nucleoside metabolite, accounts for >90% of systemic drug exposure): not a P-gp substrate	No inhibiting or inducing effects on P450 and UGT1A1.	No inhibiting or inducing effects on P450 and UGT1A1.	No inhibiting or inducing effects on P-gp, BCRP, OATP1B1, OATP1B3, OCT1, BSEP.	No inhibiting or inducing effects on P-gp, BCRP, OATP1B1, OATP1B3, OCT1, BSEP.
velpatasvir ⁵⁰⁻⁵² (NS5A inhibitor)	CYP3A4, 2C8, 2B6; OATP1B1, OATP1B3, P-gp, BCRP.	No inhibiting or inducing effects on P450.	No inhibiting or inducing effects on P450.	P-gp (34% ↑ AUC, 88% ↑ Cmax digoxin), OATP1B1, OATP1B3, OATP2B1, BCRP (169% ↑ rosuvastatin AUC)).	
voxilaprevir (GS-9857) ^{57, 58} (NS3/4A PI)	P-gp, BCRP, OATP1B1, OAT1B3. CYP3A4>>CYP1A2, 2C8.	Does not inhibit CYP or UGT1A1 enzymes.		P-gp, BCRP, OATP1B1, OATP1B3. Does not inhibit OCT1, OCT2, OAT1, OAT3 or MATE1.	
Zepatier®⁵⁹					
elbasvir ^{60, 61} (NS5A inhibitor)	CYP3A4, P-glycoprotein (P-gp) and OATP in vitro.	Does not inhibit CYP3A4	Does not induce CYP1A2, 2B6 or 3A4. ⁵⁹	BCRP (intestinal) ⁵⁹ , P-gp (in vitro only; not expected to cause clinically significant interactions via P-gp inhibition at usual	

Antiretroviral and Directly Acting Antiviral Drug Metabolism and Transporter Characteristics (Summary)

	Substrate	CYP450 and UGT		Transporters	
		Inhibitor	Inducer	Inhibitor	Inducer
				clinical doses) ⁶² Does not inhibit OATP1B ⁵⁹	
grazoprevir ^{61, 63} (NS3/4A PI)	CYP3A4, P-gp and OATP1B1	CYP2C8 (not clinically meaningful), ⁶⁴ 3A4 (weak; 34% ↑ midazolam AUC), UGT1A1 (weak)	Does not induce CYP1A2, 2B6 or 3A4. ⁵⁹	BCRP (intestinal) ⁵⁹ . Does not inhibit OATP1B ⁵⁹	
Daclatasvir-SOF					
daclatasvir ⁶⁵ (NS5A inhibitor)	CYP3A4, P-gp, OCT1. (*inhibition of P-gp alone with no/minimal CYP3A4 inhibition not expected to significantly increase daclatasvir exposure)		CYP3A4 (weak; no meaningful effect on midazolam kinetics)	P-gp (weak- moderate), weak inhibitor of OATP1B1, OCT1, and BCRP.	
sofosbuvir ⁵³ (NS5B inhibitor)	P-gp, BCRP. GS- 331007 (primary systemic nucleoside metabolite, accounts for >90% of systemic drug exposure): not a P-gp substrate	No inhibiting or inducing effects on P450 and UGT1A1.	No inhibiting or inducing effects on P450 and UGT1A1.	No inhibiting or inducing effects on P- gp, BCRP, OATP1B1, OATP1B3, OCT1, BSEP.	No inhibiting or inducing effects on P-gp, BCRP, OATP1B1, OATP1B3, OCT1, BSEP.

Key: BCRP = breast cancer resistance protein; CYP= Hepatic Cytochrome P450 isoenzyme; Substrate= route of hepatic elimination of that specific drug (specified by a specific cytochrome P450 isoenzyme); inducer = leads to more rapid clearance of substrates of a specific hepatic isoenzyme (lowers serum concentrations of the respective drug and may lead to decreased efficacy); inhibitor= leads to decreased clearance of substrates of a specific hepatic isoenzyme (increases serum concentrations of a respective drug and may lead to toxicity). OCT2 = renal organic cation transporter; P-gp= P-glycoprotein; UGT= Uridine diphosphate glucuronyltransferase.

Please note: This chart summarizes currently available data, and should be used in conjunction with other reliable sources of information. Due to the rapidly changing nature of information about HIV and HCV treatment and therapies, users are advised to recheck the information contained herein with the original source before applying it to patient care.

References

1. Bristol-Myers Squibb Canada. Reyataz (atazanavir) Product Monograph. Montreal, QC2016.
2. Janssen Inc. Prezista (darunavir) Product Monograph. Toronto, Ontario2016.
3. Elsbey R, Martin P, Surry D, Sharma P, Fenner K. Solitary inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a 2-fold increase in statin exposure. Drug Metab Dispos. 2016;44(3):398-408.
4. ViiV Healthcare ULC. Telzir (fosamprenavir) Prescribing Information. Montreal, QC2014.

Antiretroviral and Directly Acting Antiviral Drug Metabolism and Transporter Characteristics (Summary)

5. Merck Frosst Canada Ltd. Crixivan (indinavir) Product Monograph. Kirkland, QC2012.
6. AbbVie Corporation. Kaletra (lopinavir/ritonavir) Prescribing Information. Saint Laurent, Canada2016.
7. Hoffmann-La Roche Ltd. Invirase (saquinavir) Product Monograph. Mississauga, ON2012.
8. Pfizer Canada Inc. Viracept (nelfinavir) Product Monograph. Kirkland, QC2011.
9. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. *Drug Metab Dispos.* 2007;35(10):1853-9.
10. Boehringer Ingelheim. Aptivus (tipranavir) Product Monograph. Burlington, ON2011.
11. Vourvahis M, Dumond J, Patterson K, Rezk N, Tien H, Li J, et al., editors. Effects of tipranavir/ritonavir on the activity of cytochrome p450 enzymes 1A2, 2C9 and 2D6 in healthy volunteers [abstract 52]. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007 April 16-18; Budapest, Hungary.
12. AbbVie Corporation. Norvir (ritonavir) Prescribing Information. Saint-Laurent, QC2017.
13. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. *Drug Metabolism & Disposition.* 2001;29:100-2.
14. Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. *Antimicrob Agents Chemother.* 2008;52(5):1663-9.
15. Lepist EI, Zhang X, Hao J, Huang J, Kosaka A, Birkus G, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. *Kidney international.* 2014;86(2):350-7.
16. Gilead Sciences Canada Inc. Tybost (cobicistat) Product Monograph. Mississauga, ON2016.
17. German P, Liu HC, Szwarcberg J, Hepner M, Andrews J, Kearney BP, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. *J Acquir Immune Defic Syndr.* 2012;61(1):32-40.
18. Balkus JE, Palanee-Phillips T, Reddy K, Siva S, Harkoo I, Nakabiito C, et al. Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception. *Journal of acquired immune deficiency syndromes (1999).* 2017;76(2):e47-e51.
19. To EE, Hendrix CW, Bumpus NN. Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues. *Biochem Pharmacol.* 2013;86(7):979-90.
20. ViiV Healthcare ULC. Rescriptor (delavirdine) Product Monograph. Montreal, QC2009.
21. Merck Canada Inc. Pifeltro (doravirine) Product Monograph. Kirkland, QC2018.
22. Bristol-Myers Squibb Canada. Sustiva (efavirenz) Prescribing Information. Montreal, QC2015.
23. Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. *J Acquir Immune Defic Syndr.* 2008;49(5):513-9.
24. Lee LS, Pham P, Flexner C. Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by efavirenz. *Ann Acad Med Singapore.* 2012;41(12):559-62.
25. Weiss J, Herzog M, Konig S, Storch CH, Ketabi-Kiyavash N, Haefeli WE. Induction of multiple drug transporters by efavirenz. *Journal of pharmacological sciences.* 2009;109(2):242-50.
26. Janssen Inc. Intencele (etravirine) Product Monograph. Titusville, NJ2013.
27. Kakuda TN, Van Solingen-Ristea RM, Onkelinx J, Stevens T, Aharchi F, De Smedt G, et al. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects. *J Clin Pharmacol.* 2014;54(4):422-31.
28. Boehringer Ingelheim (Canada) Ltd. Viramune and Viramune XR (nevirapine) Product Monograph. Burlington, ON2011.
29. Janssen Inc. Edurant (rilpivirine) Product Monograph. Toronto, ON2017.
30. Crauwels HM, Van Heeswijk R, Stevens T, Stevens M, Buelens A, Boven K, et al., editors. The effect of TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) on CYP3A activity in vivo [abstract P_28]. 10th International Workshop on Clinical Pharmacology of HIV Therapy; 2009 April 15-17; Amsterdam.

Antiretroviral and Directly Acting Antiviral Drug Metabolism and Transporter Characteristics (Summary)

31. Zhang H, Custodio JM, Wei X, Wang H, Vu A, Ling J, et al., editors. Clinical pharmacology of the unboosted HIV integrase strand transfer inhibitor bicitegravir [abstract 40]. Conference on Retroviruses and Opportunistic Infections (CROI); 2017 February 13-16; Seattle, WA.
32. Gilead Sciences Canada Inc. Biktarvy (bicitegravir, emtricitabine, tenofovir alafenamide) Product Monograph. Mississauga 2018.
33. Reese MJ, Bowers GD, Humphreys JE, Gould EP, Ford SL, Webster LO, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. *Xenobiotica*. 2016;46(5):445-56.
34. ViiV Healthcare ULC. Vocabria (cabotegravir oral tablets) and Cabenuva (cabotegravir and rilpivirine extended release injectable suspensions) Product Monograph. Laval, QC 2020.
35. Taskar KS PA, Cozens SJ, et al., editor Prediction of renal OAT1 and OAT3 inhibition by cabotegravir using PBPK modelling [abstract 470]. Conference on Retroviruses and Opportunistic Infections (CROI); 2019 March 4-7; Seattle, WA.
36. ViiV Healthcare ULC. Tivicay (dolutegravir) Prescribing Information. Laval, QC 2018.
37. Gilead Sciences Canada Inc. Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) Product Monograph. Mississauga, ON 2018.
38. Merck Frosst Canada Ltd. Isentress and Isentress HD (raltegravir) Prescribing Information. Kirkland, QC 2017.
39. Jungmann NA, Lang D, Saleh S, Van Der Mey D, Gerisch M. In vitro-in vivo correlation of the drug-drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat. *Expert Opin Drug Metab Toxicol*. 2019;15(11):975-84.
40. Gilead Sciences Canada Inc. Descovy (emtricitabine, tenofovir alafenamide) Product Monograph. Mississauga, ON 2017.
41. Gilead Sciences Canada Inc. Viread (tenofovir disoproxil fumarate) Product Monograph. Mississauga, ON 2018.
42. Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Laboratory investigation; a journal of technical methods and pathology. 2011;91(6):852-8.
43. Matthews R, Rudd D, Fillgrove K, Fox-Bosetti S, Levine V, Zhang S, et al. 546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration. *Open forum infectious diseases*. 2018;5(Suppl 1):S203-S.
44. ViiV Healthcare. Rukobia (fostemsavir) Package Insert. Research Triangle Park, NC 2020.
45. Begley R, Lutz J, Dvory-Sobol H, West S, Kawata K, Ling J, et al., editors. Clinical evaluation of drug interactions with oral lenacapavir and probe drugs [abstract 89]. Conference on Retroviruses and Opportunistic Infections; 2021 March 6-10; Virtual.
46. Link JO, Rhee MS, Tse WC, Zheng J, Somoza JR, Rowe W, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. *Nature*. 2020.
47. Lefebvre E, Enejosa J, Chang W, Jenkins H, Ballow C, Willet M, et al., editors. Cenicriviroc (CVC) drug-drug interactions with guideline-preferred HIV antiretrovirals [abstract O_09A/O_09B]. 14th International Workshop on Clinical Pharmacology of HIV Therapy; 2013 April 22-24; Amsterdam, Netherlands.
48. ViiV Healthcare ULC. Celsentri (maraviroc) Product Monograph. Montreal, QC 2012.
49. Johnson M, Jewell RC, Peppercorn A, Gould E, Xu J, Lou Y, et al. The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects. *Pharmacol Res Perspect*. 2018;6(4):e00408-e.
50. Mogalian E, German P, Kearney BP, Cheng YY, Brainard DM, McNally J, et al. Use of multiple probes to assess transporter- and cytochrome p450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. *Clinical Pharmacokinetics*. 2016;55(5):605-13.
51. Mogalian E, Stamm L, Osinusi A, Shen G, Sajwani K, McNally J, et al., editors. Drug interaction studies between sofosbuvir/velpatasvir and boosted HIV ARV regimens [abstract 100]. Conference on Retroviruses and Opportunistic Infections (CROI); 2016 February 22-25; Boston, MA.
52. Gilead Sciences Canada Inc. Epclusa (sofosbuvir/velpatasvir) Product Monograph. Mississauga, ON 2016.
53. Gilead Sciences Canada Inc. Sovaldi (sofosbuvir) Product Monograph Mississauga, ON 2013.
54. Mathias A, editor Clinical pharmacology of DAAs for hepatitis C: what's new and what's in the pipeline. 14th International Workshop on Clinical Pharmacology of HIV Therapy; 2013 April 22-24; Amsterdam.
55. Abbvie Inc. Mavyret (glecaprevir and pibrentasvir) Prescribing Information. North Chicago, IL. 2017.
56. Kosloski MP, Dutta S, Pugatch D, Li H, Mensa FJ, Kort J, et al., editors. ABT-493 and ABT-530 combination demonstrated minimal potential for CYP-mediated drug-drug interactions [abstract THU-229]. International Liver Congress, European Association for the Study of the Liver; 2016 April 13-17; Barcelona, Spain.

Antiretroviral and Directly Acting Antiviral Drug Metabolism and Transporter Characteristics (Summary)

57. Kirby B, Taylor J, Stamm L, Song Q, Wei H, Li Y, et al., editors. Evaluation of transporter and cytochrome P450-mediated drug-drug interactions with the pan genotypic HCV NS3/4A protease inhibitor voxilaprevir (GS-9857) or sofosbuvir/velpatasvir/voxilaprevir and phenotypic probe drugs [abstracts O-24 and O-25]. 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; 2016 June 8-10; Washington, DC.
58. Gilead Sciences I. Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) Product Monograph. Foster City, CA2017.
59. Merck Canada Inc. Zepatier (elbasvir/grazoprevir) Product Monograph. Kirkland, QD2016.
60. Marshall WL, Yeh W, Caro L, Jumes P, Huang X, Dreyer D, et al., editors. Age and gender effects on the pharmacokinetics of HCV NS5A inhibitor MK-8742 [abstract PP_03]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; 2014 May 19-21; Washington, DC.
61. Caro L, Marshall WL, Feng HP, Guo Z, Wolford D, Stypinski D, et al., editors. Coadministration of HCV protease inhibitor grazoprevir with HCV NS5A inhibitor elbasvir has no effect on pravastatin but increases rosuvastatin exposure in healthy subjects [abstract 17]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; 2015 May 26-28; Washington, DC.
62. Marshall WL, Feng HP, Dupuis M, Talaty JE, Wolford D, Liu F, et al., editors. Co-administration of digoxin with the HCV NS5A protease inhibitor elbasvir has no effect on digoxin exposure in healthy subjects [abstract 64]. HEPDART 2015; 2015 December 6-10; Maui, Hawaii.
63. Yeh W, Fraser IP, Reitmann C, Caro L, Mitselos A, Deneff J-F, et al., editors. Pharmacokinetic interaction of HCV protease inhibitor MK-5172 and ritonavir in healthy subjects [abstract 52]. HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis; 2013 December 8-12; Big Island, Hawaii.
64. Wolford D, Caro L, Guo Z, Jumes P, Gartner M, Bethel-Brown C, et al., editors. No clinically meaningful pharmacokinetic interactions between HCV protease inhibitor grazoprevir and montelukast (a CYP2C8 substrate) in healthy subjects [abstract 66]. HEPDART 2015; 2015 December 6-10; Maui, Hawaii.
65. Bristol-Myers-Squibb. Daklinza (daclatasvir) Summary of Product Characteristics. European Union2014.